VentureBeat

Posts Tagged ‘co:Phenomix’

TODAY’S HEADLINES:

progentech-logo-150px.gifProGenTech takes in $21M for DNA purification systems – ProGenTech, an “East-West” tool and equipment maker, raised $21 million in a third funding round. Investors included Bay City Capital of San Francisco and DT Capital of Shanghai.

ProGenTech makes purification systems that isolate DNA from blood or other biological samples for processing and analysis. The startup is based in Shanghai and Emeryville, Calif.

phenomix-logo-150px.jpgDiabetes-drug maker Phenomix raises $18M while seeking IPO – Phenomix, a San Diego biotech developing new diabetes drugs, raised a total of $73.3 million in its third funding round, according to a recent amendment to its IPO filing. VentureWire reports that the startup had raised $55 million as of March 2007, suggesting the company pulled in an additional $18.3 million since then.

Phenomix claims to be a “fast follower” in drug development, a company that aims to create better versions of drugs that take aim at biological mechanisms already proven to work by earlier drugs. Its leading drug candidate is an inhibitor of dipeptidyl peptidase-4, or DPP-4, an enzyme that plays a role in insulin production, for use in type 2 diabetes. The company is looking to raise $86.3 million in its IPO.

biotrove-logo-150px.gifGenome-tool maker BioTrove gets $23M in preparation for IPO – BioTrove, a Woburn, Mass., biomedical equipment maker, raised $22.7 million in a third funding round just prior to filing for an IPO, according to its SEC registration statement. The funding was first reported by VentureWire.

The company makes tools and systems for DNA analysis and drug screening. It filed yesterday to raise $75 million in its initial offering. BioTrove’s backers in the latest fundraising included Catalyst Health and Technology Partners, CB Health Ventures, Vox Equity Partners, and Fletcher Spaght Ventures.

TODAY’S HEADLINES:

brightheart-vet-logo-150px.jpgBrightHeart Vet corrals $29M to acquire animal hospitals — BrightHeart Veterinary Centers, an Armonk, N.Y., operator of veterinary hospitals, raised $28.5 million in a funding round intended to further the chain’s expansion. Investors included LLR Partners and Caltius Mezzanine.

BrightHeart currently runs facilities in New York, Connecticut, Illinois and Alberta, Canada, two of which it acquired just last week. The company intends to continue growing via acquisition.

aviaradx-logo-150px.gifAviaraDx raises $8M for cancer diagnostics — AviaraDx, a Carlsbad, Calif., developer of molecular cancer diagnostics, raised $8 million in a first funding round, peHUB reports, citing a regulatory filing. AviaraDx was spun out of the former Arcturus Bioscience, whose other assets were mostly acquired by Molecular Devices in 2006.

AviaraDx sells tests that identify tumors by their molecular “fingerprints” and predice which breast-cancer tumors are most likely to recur following surgery. The company isn’t providing much detail on its future development plans.

valor-medical-logo-150px.jpgValor Medical aims for $15M for brain-aneurysm treatment — Valor Medical, a San Diego device maker developing a new polymer-based treatment for brain aneurysms, is seeking $15 million in a second funding round, VentureWire reports. The company’s Neucrylate is a substance designed for use as a “filler” in aneurysms, which are dangerous arterial swellings that can rupture unexpectedly. Valor intends to begin clinical testing this year.

phenomix-logo-150px.jpgPhenomix, diabetes and hepatitis drug maker, files for $86M IPO — San Diego-based Phenomix, a biotech developing new drugs for diabetes and hepatitis, filed to raise $86.3 million in an initial offering. The company aims to be a “fast follower” that develops new drugs that address biological mechanisms that have been “validated” by successful drugs elsewhere.

Top Stories

Recent Comments

Powered by Disqus

Recent Guest Columnists

Job Board

Links

Venturebeat Writers

  • For advertising, contact .
  • Log in

Font Size

Xanodyne joins a growing number of biopharmaceutical and life science companies calling it quits on going public, at least for now. The Newport, Ky.-based firm withdrew its filing on Friday, citing poor market conditions — it had been waiting since November. Not that the company is really hurting. It’s raised about $232 million to date, and [...]

More ...

Biopharmaceuticals company Phenomix withdrew its filing to go public yesterday and right away announced a $340-million collaboration deal with Forest Laboratories. The IPO, intended to raise $86.3 million, had been pending since January.
Forest will aid the San Diego-based firm in the development of its diabetes treatment, dutogliptin, which is currently in its third phase of [...]

More ...